VEGFD and neoplasm: Our current study aimed to further address these issues, and we found that YL529 blocked VEGF-D-induced lymphangiogenesis and inhibited tumor growth efficiently at the dosage of 150 mg/kg/day or even less, as a result, affected mice have significantly better survival rate.